BioSpace News Archive

Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.

Jazz Pharmaceuticals plc announced initial positive results from a Phase 2/3 trial of intramuscular administration of Rylaze™ in adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who have developed hypersensitivity or silent inactivation to an E. coli-derived asparaginase.

Sangamo Therapeutics, Inc. announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease.

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel, an investigational B-cell maturation antigen -directed chimeric antigen receptor T-cell therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma.

Global Blood Therapeutics, Inc. announced positive results from real-world and long-term studies with Oxbryta® tablets for the treatment of sickle cell disease.

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that updated initial safety and efficacy findings from the Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia were presented in an oral session at the 63rd American Society of Hematology Annual Meeting.

bluebird bio, Inc. announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel gene therapy for sickle cell disease, including further analyses from its pivotal cohort, HGB-206 Group C, following enhancements to the manufacturing protocols and treatment process.

StemiRNA, a leader in research and development of mRNA therapeutics, welcomes Dr. Jack Hu as Chief Financial Officer.